Experimental cancer drug BGB-3245 studied in early trial
NCT ID NCT04249843
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tested an experimental drug called BGB-3245 (brimarafenib) in 109 people with advanced solid tumors that had not responded to standard treatments. The drug is designed to block certain proteins that help cancer grow. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated early, but it gathered important safety and dosing information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-3245 (brimarafenib), a drug taken by mouth that targets certain cancer-related proteins
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not shrink tumors or may cause side effects, and it is unclear if it will work for most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blacktown Hospital
Blacktown, New South Wales, 2148, Australia
-
Cedars Sinai Medical Center
Beverly Hills, California, 90212, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
One Clinical Research
Nedlands, Perth, 6009, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 2010, Australia
-
The Kinghorn Cancer Centre, St Vincent Hospital Sydney
Sydney, New South Wales, 2010, Australia
-
University of Virginia Comprehensive Cancer Centre
Charlottesville, Virginia, 22903, United States